Food and Drug Administration (FDA) Approves the First Deuterated Drug, AUSTEDO™ by Teva

This deuterated drug was developed for the treatment of chorea, random involuntary twisting movements, which is associated with Huntington’s disease (HD). This newly developed deuterated drug will not only reduce these symptoms but will help improve the quality of life of the tens of thousands of patients and the families of those suffering from HD. CIL congratulates Teva on this ground-breaking accomplishment. As a the long-term deuterium supplier worldwide, CIL looks forward to serving the pharmaceutical industry as it advances in improved drug development and remains committed to improving the quality of life of others.